Japanese drugmaker Eisai (TYO: 4523) today announced that the in-house-discovered and developed orexin receptor antagonist ...

Centessa Pharmaceuticals announced significant progress in its orexin receptor 2 (OX2R) agonist pipeline, particularly with ORX750, which is undergoing a Phase 2a study for narcolepsy type 1 (NT1 ...

“This was a productive quarter for Centessa, marked by steady progress across our OX2R agonist pipeline,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa. “The orexin pathway ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 ...

DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R).

Oveporexton is an investigational oral orexin receptor 2-selective agonist designed to restore orexin signaling to address ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking ...

Oveporexton (TAK-861) is a highly selective oral OX2R agonist that crosses the blood−brain barrier and has been shown to improve wakefulness in preclinical models 16,17 and in sleep-deprived ...

About ALKS 2680 ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2 ...

Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China ...

Piper Sandler initiated coverage on the company with an Overweight rating and a price target of $38.00, citing the potential of Centessa’s orexin receptor 2 (OX2R) agonist franchise ...